Peter Marks (Jim Lo Scalzo/Pool via AP Images)
January 10, 2024 11:17 AM ESTUpdated 01:32 PM
Cell/Gene Tx
FDA+

FDA's CBER chief hints at ex­pand­ing Sarep­ta's gene ther­a­py la­bel, sends stock up 25%

Zachary Brennan

Senior Editor

De­spite a failed con­fir­ma­to­ry tri­al an­nounced in Oc­to­ber, the FDA’s Pe­ter Marks, the top reg­u­la­tor for all cell and gene ther­a­pies in the US, is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times